Becton, Dickinson and Company (BD) has introduced a new and easy-to-use advanced ultrasound device with a specialised probe to facilitate optimal IV placement.
Dubbed the BD Prevue II System, the new ultrasound device has a BD Cue needle tracking system that helps in providing a quality ultrasound image of the needle trajectory.
The device will enable safer and easier vascular access procedures for clinicians and patients.
Compatible with BD Cue needle tracking-enabled catheters, the system comprises clinician-friendly features to help bolster the use of ultrasound in IV placement.
Eric Borin, president of BD medication delivery solutions worldwide, said: “Difficult IV access remains far too common today, but the availability of the BD Prevue II System supports a future where every needlestick has a predefined pathway for successful placement.
“BD is advancing the vision of a ‘One-Stick Hospital Stay’ and first-stick success is the first requirement to fulfil that vision.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData“First-stick success also reduces the pain and anxiety patients often experience while undergoing multiple IV access attempts and provides clinicians with IV workflow efficiencies and confidence.”
The system’s specialised probe helps clinicians to use the technology without altering their field of view or current insertion technique.
Simulated studies demonstrated that combining a needle tracking system with ultrasound guidance allows for a decrease in the number of attempts and time to achieve successful vessel access.
The BD Prevue II System is expected to further accelerate the company’s “One-Stick Hospital Stay” vision to cut down unnecessary needlesticks by selecting the right vascular access device.